GLP Meds: The Class, Mechanism, and Genetics

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide comes from the PlexusDx Education Hub, our library of evidence-based writing on GLP-1 therapies, weight-management protocols, and the genetics that inform each metabolic decision. Browse all Peptides & GLP-1 education.

The phrase "GLP meds" points at a whole drug class rather than a single pill or pen. To use the term well, it helps to understand the hormone the class imitates, the mechanical trick that turns a fleeting body signal into a lasting medication, which specific agents belong on the list, what they are approved to treat, and the safety language they share. Genetics run underneath all of it, describing the biology these drugs act on.

The hormone the class is built to imitate

Glucagon-like peptide-1 is an incretin hormone released by enteroendocrine L-cells in the small intestine whenever you eat. It prompts glucose-dependent insulin secretion from pancreatic beta cells, dials down glucagon output from alpha cells, slows the rate at which the stomach empties, and sends satiety signals to the hypothalamus. Its catch is speed: native GLP-1 survives only minutes in circulation before the enzyme DPP-4 breaks it down.

Turning a minutes-long signal into a weekly one

GLP-1 receptor agonists are engineered peptides, and in newer cases small molecules, that latch onto the GLP-1 receptor while resisting DPP-4 degradation. That resistance stretches the half-life from minutes into hours or days, letting a single dose reproduce native GLP-1's effects at a pharmacological scale: glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, and appetite reduction through central satiety signaling. One subclass goes further — GIP/GLP-1 dual agonists such as tirzepatide also bind the GIP receptor, layering a second incretin mechanism on top of the first.

Which agents make up the class

As of April 2026, the roster of FDA-approved agents divides cleanly by receptor coverage.

Single GLP-1 receptor agonists

These include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and semaglutide (Ozempic, Wegovy, Rybelsus). Lixisenatide was marketed historically but has been discontinued in the United States.

Dual and investigational agents

Tirzepatide (Mounjaro, Zepbound) is the GIP/GLP-1 dual agonist. The triple agonist retatrutide, which targets GLP-1, GIP, and glucagon, has Phase 3 data but remains investigational and is not FDA-approved. Emerging oral non-peptide agonists such as orforglipron are in late-stage development.

What the class is approved to treat

Indications track the individual compound and product rather than the class as a whole. Most agents carry a type 2 diabetes indication. Chronic weight management belongs to Wegovy, Saxenda, and Zepbound. Cardiovascular risk reduction in type 2 diabetes applies to Ozempic, Trulicity, Victoza, and Rybelsus. Zepbound added obstructive sleep apnea in adults with obesity in December 2024, and certain products carry pediatric indications. Because FDA labeling dictates which product treats which condition, the specifics belong in a conversation with your provider.

The safety language every label shares

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk seen in rodent studies. A personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, is a contraindication. The most frequent side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — and tend to peak during dose escalation. Reported serious events include pancreatitis, gallbladder problems, and acute kidney injury in the setting of dehydration.

Your genes describe the terrain, not the outcome

Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1 signaling, appetite regulation, and energy balance. They operate at the pathway level: they characterize the biological ground every agent in the class works on, without forecasting how you will respond to any one compound. The PlexusDx Precision Peptide Genetic Test surveys 14 pathways, 49 peptides, 150+ genetic insights to map that ground. It never predicts drug response — it is trait education you bring to your provider. For the pathway primer, see What Is GLP-1?.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Related reading includes GLP-1 Hormone and GLP-1 Receptor Agonist.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

What defines a GLP-1 receptor agonist?

It is a peptide, or an emerging small molecule, that binds the GLP-1 receptor and resists rapid enzymatic breakdown. That combination drives glucose-dependent insulin secretion, slows gastric emptying, and signals fullness. FDA-approved examples include semaglutide, liraglutide, dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide.

How do dual agonists differ from single ones?

Single agonists engage only the GLP-1 receptor, while GIP/GLP-1 dual agonists like tirzepatide also bind the GIP receptor for a second incretin mechanism. Trial programs such as SURPASS and SURMOUNT suggest the dual approach may produce larger mean effects on weight and glycemic control in some study populations.

Does the Precision Peptide Genetic Test tell me which med will work?

No. It does not predict response to any specific compound in the class. It examines pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, giving you upstream context that applies broadly across GLP-1 and GIP/GLP-1 agents alike.

Who should avoid these medications?

People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated across every label in the class. Those with severe gastrointestinal disease or a history of pancreatitis need careful clinical review. Share your full history with a provider first.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.